Skip to main content
SpringerLink
Log in

Immunophenotypic, cytogenetic and clinical features of 192 AML patients in China

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Immunophenotypic characterization of the leukemic cells has been widely used as a tool for diagnosis, classification and prognosis of leukaemia. A total of 192 Chinese patients with acute myeloid leukemia (AML) were immunophenotyped by flow cytometry using a panel of monoclonal antibodies. Among the 192 patients enrolled in this study, 125 cases were also subjected to karyotype analysis by G-banding technology. We found that CD33, CD13, MPO and CD117 were the most commonly expressed antigens in AML. A combination of intensive autofluorescence, both CD34− and HLA-DR−, and high expression of CD13, CD33 and MPO had significant value for M3 diagnosis. CD14 was expressed only in M4 and M5, and both intensive positivity of CD64 and CD15 with high expression of HLA-DR may suggest great possibility for diagnosis of M5. Lymphoid markers expression was documented in 47.9% of the 192 AML cases analyzed. CD56 (26.0%) and CD7 (20.8%) were the most commonly expressed lymphoid markers in AML patients. Abnormal karyotypes were detected in 76 out of 125 (60.8%). Higher CD34 positivity was found in LymAg+ group (77.2%) than in LymAg− group (48.0%). Our results indicate that immunophenotype analysis was useful for AML diagnosis and classification and the immunophenotype did have relevance to the abnormal cytogenetic changes and clinical features in AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO Classification of tumours of haematopoietic and lymphoid tissues., 4th edn. International Agency for Research on Cancer, Lyon

    Google Scholar 

  2. Dunphy CH (2004) Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med 128:1004–1022

    PubMed  Google Scholar 

  3. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM et al (1995) Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. Cancer Genet Cytogenet 84:60–68

    Article  PubMed  CAS  Google Scholar 

  4. Kaleem Z, Crawford E, Pathan MH, Jasper L, Covinsky MA, Johnson LR et al (2003) Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 127:42–48

    PubMed  Google Scholar 

  5. Auewarakul CU, Promsuwicha O, U-Pratya Y, Pattanapanyasat K, Issaragrisil S (2003) Immunophenotypic profile of adult acute myeloid leukemia (AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol 21:153–160

    PubMed  Google Scholar 

  6. Hans CP, Finn WG, Singleton TP, Schnitzer B, Ross CW (2002) Usefulness of antiCD117 in the flow cytometric analysis of acute leukemia. Am J Clin Pathol 117:301–305

    Article  PubMed  CAS  Google Scholar 

  7. Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML, Arber DA (1998) The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol 109:211–220

    PubMed  CAS  Google Scholar 

  8. Paietta E (2003) Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:369–385

    Article  PubMed  CAS  Google Scholar 

  9. Zheng J, Wang X, Hu Y, Yang J, Liu J, He Y et al (2008) A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China. Cytom B Clin Cytom 74:25–29

    Article  Google Scholar 

  10. Hayden PJ, O’Connell NM, O’Brien DA, O’Rourke P, Lawlor E, Browne PV (2006) The value of autofluorescence as a diagnostic feature of acute promyelocytic leukemia. Haematologica 91:417–418

    PubMed  Google Scholar 

  11. Reiter A, Lengfelder E, Grimwade D (2004) Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol 112:55–67

    Article  PubMed  Google Scholar 

  12. Krasinskas AM, Wasik MA, Kamoun M, Schretzenmair R, Moore J, Salhany KE (1998) The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol 110:797–805

    PubMed  CAS  Google Scholar 

  13. Dunphy CH, Orton SO, Mantell J (2004) Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and the contribution of flow cytometric immunophenotyping to the evaluation of absolute monocytoses. Am J Clin Pathol 122:865–874

    Article  PubMed  Google Scholar 

  14. Bene MC (2005) Immunophenotyping of acute leukaemias. Immunol Lett 98:9–21

    Article  PubMed  CAS  Google Scholar 

  15. Dunphy CH, Tang W (2007) The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med 131:748–754

    PubMed  CAS  Google Scholar 

  16. Abdelhaleem M (2007) Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia. Exp Mol Pathol 83:259–263

    Article  PubMed  CAS  Google Scholar 

  17. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G et al (1998) Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 12:1056–1063

    Article  PubMed  CAS  Google Scholar 

  18. Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi T, Shirakawa S et al (1993) Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 81:2399–2405

    PubMed  CAS  Google Scholar 

  19. Chang H, Salma F, Yi Q, Patterson B, Brien B, Minden MD (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 28:43–48

    Article  PubMed  CAS  Google Scholar 

  20. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G et al (2000) The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 96:870–877

    PubMed  CAS  Google Scholar 

  21. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR et al (1997) Expression of the neural cell adhesion molecular CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(821)(q22q22). Blood 90:1643–1648

    PubMed  CAS  Google Scholar 

  22. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S et al (1999) CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 17:293–297

    PubMed  CAS  Google Scholar 

  23. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Sestigiani C et al (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15:1161–1164

    Article  PubMed  CAS  Google Scholar 

  24. Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F et al (2004) PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 64:7399–7404

    Article  PubMed  CAS  Google Scholar 

  25. Valbuena JR, Medeiros LJ, Rassidakis GZ, Hao S, Wu CD, Chen L et al (2006) Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol 126:235–240

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Authors thank the staff in the Laboratory and Department of Hematology in Shengjing Hospital of China Medical University for AML samples.

Conflict of interest statement

We have no conflict of interest.

Author information

Authors and Affiliations

  1. Laboratory of Hematology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, 110022, Shenyang, China

    Haixia Tong, Jihong Zhang & Yu Ma

  2. Section of Health Testing, College of Public Health, China Medical University, No. 92 Northsecond Road, Heping District, 110001, Shenyang, China

    Chunwei Lu

  3. Department of Hematology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, 110022, Shenyang, China

    Zhuogang Liu

Authors
  1. Haixia Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunwei Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jihong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhuogang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haixia Tong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tong, H., Lu, C., Zhang, J. et al. Immunophenotypic, cytogenetic and clinical features of 192 AML patients in China. Clin Exp Med 9, 149–155 (2009). https://doi.org/10.1007/s10238-009-0030-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-009-0030-8

Keywords

Search

Navigation